Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-EGFR-IL13Ra2 Cells in EGFR-Amplified Recurrent Glioblastoma
NCT05168423Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Feb 2023
- Primary completion
- Dec 2039
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of bivalent CAR-T (anti-EGFR) in glioblastoma (GBM) (5 cohorts), sponsored by University of Pennsylvania. Primary endpoints: Number of Subjects with treatment related adverse events at 15 years, Number of subjects with dose-limiting toxicities at 28 days and 3 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
bivalent CAR-T (anti-EGFR)
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05168423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168423.